Everyone loves the miracle story. Hospice. No options left. Then a clinical trial. Then a second chance. For me, that second chance came through the early feasibility study of the EVOQUE transcatheter tricuspid valve replacement. I later continued follow-up as part of the TRISCEND II research studying this therapy for people living with severe tricuspid regurgitation, But what people don’t talk about very often is what happens after the miracle. When the swelling finally s

When people talk about clinical trials, they often talk about outcomes, data, and approvals. But what mattered most in my journey wasn’t just that a trial existed. It was how supported or unsupported I felt while living inside it. Behind every study are real people trying to survive long enough to reach the next option. And sometimes the hardest part isn’t the science. It’s the space in between. Here are some of the realities I lived through that rarely show up in trial repor

Structural heart disease is not always a one valve problem. In today’s world of rapid transcatheter innovation, new clinical trials for aortic, mitral, and tricuspid valve disease are changing lives. Patients who once had no options now have real hope through structural heart clinical trials and transcatheter therapies. Innovation is moving fast, and that is something to celebrate. But here is the question we need to start asking: what happens when a patient who joined one he

They say a picture is worth a thousand words. But when you live with heart valve disease, one medical note can explain years of symptoms. For a long time, I felt my body changing. I was tired all the time. My chest felt heavy. The swelling kept getting worse. But the focus stayed on my past surgeries and my pulmonary arteries. Meanwhile, something else was quietly progressing, severe tricuspid regurgitation. My echocardiograms showed moderate leakage in 2005. By 2014, it was

I’ve experienced the healthcare system at its limits and I’ve experienced its breakthroughs. My journey took me from a hospital bed to hospice care to a clinical trial that changed the course of my life. So when I say clinical research should start with patients, I’m speaking from lived experience, from the places where the healthcare system didn’t quite hold. Patient-centered research sounds good on paper. And I truly believe most research teams care. I’ve met brilliant clin

🫀 The 65+ Pulse Check You can’t protect what you don’t listen to. When was the last time someone listened to your heart? ❤️‍🩹 For many people over 65, shortness of breath, constant fatigue, or feeling “just a little slower” gets brushed off as normal aging. It’s not. These can be early warning signs of heart valve disease, a condition that is often treatable if caught early. At HeartBridge Collective (HBC), we believe no one should lose their independence or quality of life

Life can change fast . Sometimes it’s one symptom. One scan. One “we’re not sure yet.” And suddenly you’re on a long road you never asked to be on. My story isn’t just about heart disease. It started with an idiopathic rare disease  that most people including doctors have never even heard of. That rare disease set off a chain reaction that eventually led to something wild: a 52mm EVOQUE transcatheter tricuspid valve replacement —basically a new heart valve placed through a ca

Tricuspid Valve Regurgitation, Explained in Plain Language I’m listening to a non-invasive cardiologist  explain tricuspid valve regurgitation (TR)  grades, and I hear this a lot: “Mild” and “trace” are clinically irrelevant.They don’t matter. I understand what that means medically .But here’s the truth — it still matters to patients. Let me explain why 👇 🩺 What Doctors Are Taught In medical training and guidelines: Trace or mild TR is very common Many healthy people have i

❤️‍🩹 A patient’s perspective from someone who lived early feasibility When you’re one of the first people to receive a new heart valve, you learn pretty quickly that innovation is both a miracle and an evolving standard of care. I was an early feasibility EVOQUE patient — part of the group whose outcomes helped shape future FDA approval. The valve saved my life. But being in that first wave also meant stepping into a space where long-term answers were still being written. Th

January 2026 marks the start of my fifth year living with the EVOQUE tricuspid valve, which I received through the TRISCEND II...

💔 A Moment I’ll Never Forget. Right before I went into hospice, I could feel my body getting weaker every day. Still, I tried to keep...

How Heart Valve Disease Taught Me to Listen to My Body's Other Rhythms Hey everyone, you know I'm a big advocate for heart valve disease...

Redefining “Normal” After Illness The bridge between real stories and how care should be designed After a major health scare, surgery, or...

🫀 Real Advocacy. Real Impact. Tori Lungren’s Two-Story Reminder That Your Voice Might Be the Most Important Tool You Have 🩷 PATIENT...

Every life-saving treatment starts with a clinical trial . You can’t approve a cure no one is willing to test. I didn’t say yes to the...

Being quiet won’t protect you—but being informed just might.  If you're anything like me, you didn’t choose this health journey—but here...

Because Some Wounds Don’t Show Up on X-Rays I’ve talked about this before, but I don’t think I realized just how real it was until now....

Lived Experience Isn’t Optional Data. It’s the Truth You Can’t See in a Test Doctors vs. Patients: Why Being Heard Means Everything in...

Heart stuff is never simple, especially when you’ve walked through it like I have. But sometimes, we get a bit of good news in the...

Why the people deciding your treatment aren’t the ones trained to treat you. Right?! It’s absolutely wild. Your medically trained doctor,...